Clinical Trials in Phoenix

Showing 861-880 of 14,291 trials

Single Arm Romiplostim to Prevent CIT

NCT07048249

The goal of this clinical trial is to to assess the efficacy of romiplostim as a supportive care measure in patients with a new diagnosis of Ewing sarcoma receiving interval-compressed chemotherapy. The main questions it aims to answer are: 1. To demonstrate the efficacy of romiplostim in patients with newly diagnosed Ewing sarcoma, measured specifically as the rate of CIT, defined as a failure to achieve platelet recovery (≥ 75,000/µL post nadir, without transfusion, or a platelet count sufficient to resume chemotherapy per provider and institutional standard) within 7 days of planned chemotherapy cycle start, measured during the continuation phase (cycle 7 to end of cycle 13 or 16, per AEWS0031/AEWS1221, or AEWS1031 respectively) of interval-compressed chemotherapy (every 2 week vincristine/cyclophosphamide +/- doxorubicin and ifosfamide/etoposide chemotherapy) as compared to published institutional historical control rate. 2. To determine the safety of incorporation of romiplostim supportive care when given concurrently with Ewing sarcoma therapy. 3. To determine the feasibility of incorporation of romiplostim supportive care into upfront Ewing sarcoma regimens.

Ewings SarcomaChemotherapy Induced Thrombocytopenia

Children's Hospital Medical Center, Cincinnati26 participantsStarted Jan 2024

Phoenix, Arizona, United States • Cincinnati, Ohio, United States

RECRUITING< 1 mile

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

NCT02815891

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.

Nonalcoholic Fatty LiverNonalcoholic Steatohepatitis

Target PharmaSolutions, Inc.15,000 participantsStarted Jul 2016

Phoenix, Arizona, United States • Palo Alto, California, United States • Pasadena, California, United States +71 more locations

Single Arm Romiplostim to Prevent CIT

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Find Trials by Condition in Phoenix

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors

Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae

Study of DF1001 in Patients With Advanced Solid Tumors

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

A Study of DF6002 Alone and in Combination With Nivolumab

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test

A Study of Ponsegromab in People With Heart Failure

SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa